纳武利尤单抗在错配修复缺陷非结直肠癌中有效:NCI-MATCH研究Z1D子方案结果
NCI-MATCH是一项覆盖超过1100个中心的大型精准肿瘤学研究,按肿瘤分子改变将复发或难治性恶性肿瘤患者分配至平行II期靶向治疗子研究。Z1D子方案评估纳武利尤单抗在错配修复缺陷(MMR-d)非结直肠癌患者中的活性,主要终点为RECIST 1.1客观缓解率(ORR)。结果显示,在4902例筛查患者中2%为IHC定义的MMR-d,42例可评估患者ORR为36%,中位总生存17.3个月,毒性以低级别为主,提示纳武利尤单抗在多种组织学类型的MMR-d非结直肠癌中具有前景。
要点
- MMR-d非结直肠癌占筛查患者的2.0%,纳武利尤单抗ORR达36%。
- 常见组织学类型包括子宫内膜样腺癌、前列腺腺癌和子宫癌肉瘤。
- 中位总生存17.3个月,毒性以低级别为主。
核心结论
- 纳武利尤单抗在MMR-d非结直肠癌中显示出有前景的抗肿瘤活性,覆盖多种组织病理学类型。
研究设计与样本
- NCI-MATCH试验Z1D子方案,基于肿瘤分子改变分配治疗的平行II期研究,纳入复发或难治性、ECOG体能状态≤1、器官功能良好的MMR-d非结直肠癌患者。
- MMR-d定义为免疫组化(IHC)显示MLH1或MSH2核表达完全缺失,排除MMR-d结直肠癌患者。
- 纳武利尤单抗3 mg/kg每2周(28天为一周期),第4周期后改为480 mg每4周静脉给药,每2周期评估疗效,主要终点为RECIST 1.1 ORR。
主要发现
- 4902例筛查患者中2%为IHC定义的MMR-d肿瘤。
- 42例可评估患者入组,中位年龄60岁,中位既往治疗线数为3线。
- 最常见组织学类型为子宫内膜样子宫内膜腺癌(n=13)、前列腺腺癌(n=5)和子宫癌肉瘤(n=4)。
- ORR为36%(42例中15例),另有21%的患者疾病稳定。
- 估计6、12、18个月无进展生存率分别为51.3%(90% CI,38.2%至64.5%)、46.2%(90% CI,33.1%至59.3%)和31.4%(90% CI,18.7%至44.2%);中位总生存17.3个月。
关键数值与推荐
- MMR-d定义:IHC显示MLH1或MSH2核表达完全缺失。
- 主要终点ORR为36%(15/42),RECIST 1.1标准。
临床怎么用
- 对复发或难治性非结直肠癌患者,可考虑通过IHC检测MMR状态以筛选可能从纳武利尤单抗获益的MMR-d人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest national precision oncology study to date (> 1,100 sites) of patients with relapsed or refractory malignancies, assigned patients to targeted therapy in parallel phase II studies based on tumor molecular alterations. The anti-programmed death receptor 1 inhibitor nivolumab previously showed activity in mismatch repair (MMR)-deficient colon cancer. We hypothesized that nivolumab would have activity in patients with MMR-deficient, noncolorectal tumors. PATIENTS AND METHODS: Eligible patients with relapsed or refractory tumors, good end-organ function, and Eastern Cooperative Oncology Group performance status of ≤ 1 underwent tumor biopsy for centralized screening of molecular alterations. MMR deficiency was defined by complete loss of nuclear expression of MLH1 or MSH2 MMR gene products by immunohistochemistry (IHC). Patients with MMR-deficient colorectal cancer were excluded. Nivolumab, 3 mg/kg every 2 weeks (28-day cycles) and 480 mg every 4 weeks after cycle 4, was administered intravenously. Disease reassessment was performed every 2 cycles. The primary end point was RECIST 1.1 objective response rate (ORR). RESULTS: Two percent of 4,902 screened patients had an MMR-deficient cancer by IHC. Forty-two evaluable patients were enrolled, with a median age of 60 years and a median of 3 prior therapies. The most common histologies were endometrioid endometrial adenocarcinoma (n = 13), prostate adenocarcinoma (n = 5), and uterine carcinosarcoma (n = 4). ORR was 36% (15 of 42 patients). An additional 21% of patients had stable disease. The estimated 6-, 12-, and 18-month progression-free survival rates were 51.3% (90% CI, 38.2% to 64.5%), 46.2% (90% CI, 33.1% to 59.3%), and 31.4% (90% CI, 18.7% to 44.2%), respectively. Median overall survival was 17.3 months. Toxicity was predominantly low grade. CONCLUSION: A variety of refractory cancers (2.0% of those screened) had MMR deficiency as defined in NCI-MATCH. Nivolumab has promising activity in MMR-deficient noncolorectal cancers of a wide variety of histopathologic types.
引用
- Azad NS, Gray RJ, Overman MJ, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2019. PMID: 31765263. doi:10.1200/JCO.19.00818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。